Abstract
Objectives: Understanding trends in characteristics of early phase trials that allow minors with cancer to participate may inform additional efforts to improve cancer drug development for young people.Methods: We accessed data for oncology phase 1 or phase 1/2 trials in the United States from ClinicalTrials.gov with lower age bound for eligibility P ≤ .02). No other temporal trends were seen. The median times from first‐in‐adult to first‐in‐pediatric for monotherapy and combination trials were 5.7 and 3.3 years, respectively.Conclusion: The paucity of clear temporal trends highlights the need for innovation in early drug development for young people. Our analysis serves as a benchmark against which to evaluate initiatives to improve pediatric cancer drug development.

This publication has 20 references indexed in Scilit: